Hims & Hers expands obesity drug access via partnership with Eli Lilly

Hims & Hers is partnering with Eli Lilly to offer FDA-approved weight-loss drugs to eligible patients, according to a report by Yahoo Finance published Friday. The announcement frames the effort as a way to expand access to prescription obesity treatments while strengthening Hims & Hers’s obesity-care platform.

Under the reported collaboration, Hims & Hers will provide two Eli Lilly medicines for weight management: Zepbound and Foundayo. Zepbound is Lilly’s branded prescription treatment for chronic weight management, while the Yahoo Finance report names Foundayo as another FDA-approved weight-loss option included in the program.

For Hims & Hers, the move is part of a broader strategy to use its telehealth model to connect patients with prescription therapies, from initial screening to ongoing treatment. By adding Lilly’s obesity medicines to its menu, the company is effectively broadening the set of FDA-approved weight-loss treatments available through its digital care pathway.

For Eli Lilly, the partnership offers a distribution channel that can reach patients who may not otherwise seek obesity care in person. Lilly has increasingly emphasized weight management as a major growth area, and adding its medicines to additional prescribing pathways can help maintain momentum for its portfolio.

Neither company, in the Yahoo Finance report, provided granular details on how prescribing will work in day-to-day practice, such as which clinical steps will be handled by Hims & Hers versus Lilly-connected resources, how eligibility determinations will be documented, or what specific patient monitoring protocols will be used beyond the fact that the drugs are FDA-approved.

The report also did not lay out pricing or reimbursement terms, such as whether patients will face copays tied to specific insurance plans or whether any payment assistance program is planned as part of the rollout. It likewise did not specify a timeline for when the drugs would become available to patients, beyond describing the partnership as a means of expanding access.

Broader context: the obesity-care market has become increasingly competitive as more branded prescription medicines reach scale and as digital health companies look for differentiated offerings that can convert demand into ongoing patient engagement. Partnerships like this can matter not only for patient access, but also for the economics of prescribing volume in a market where coverage decisions and cost sensitivity often determine patient persistence.

What remains unclear from the publicly stated report is how quickly patient capacity will ramp, whether the companies expect demand to exceed current supply of the medicines, and whether the partnership includes any performance targets or marketing commitments. Those elements, if they exist, were not described in the Yahoo Finance piece, leaving investors and patients to wait for additional details through company releases or regulatory communications.